Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria
Long-term and re-treatment with ligelizumab was well tolerated and efficacious in patients with CSU, aligning with the short-term outcomes observed in the Phase 3 PEARL studies.
Authors
- Alis Burciu
- Manmath Patekar (ORCID: https://orcid.org/0000-0001-9754-890X)
- Solange Oliveira Rodrigues Valle (ORCID: https://orcid.org/0000-0001-5512-7349)
- Knut Brockow (ORCID: https://orcid.org/0000-0002-2775-3681)
- Roberta Fachini Jardim Criado (ORCID: https://orcid.org/0000-0003-2482-3047)
- Y. Joubert
- Gordon Sussman (ORCID: https://orcid.org/0000-0002-2202-2513)
- Diana Deleanu (ORCID: https://orcid.org/0000-0002-8431-8352)
- Thomas Severin (ORCID: https://orcid.org/0000-0001-7203-2042)
- Vineeth Varanasi (ORCID: https://orcid.org/0000-0002-6542-5777)
- Adam Reich (ORCID: https://orcid.org/0000-0002-5573-1754)
- Eva Hua (ORCID: https://orcid.org/0000-0001-5781-170X)
- Chia‐Yu Chu (ORCID: https://orcid.org/0000-0002-9370-3279)
- Koremasa Hayama (ORCID: https://orcid.org/0000-0001-8651-2493)
- Sarbjit S. Saini (ORCID: https://orcid.org/0000-0001-8522-2742)
- M. Denguezli (ORCID: https://orcid.org/0000-0002-4176-2744)
- Raisa Meshkova (ORCID: https://orcid.org/0000-0002-7806-9484)
- Marcus Maurer (ORCID: https://orcid.org/0000-0002-4121-481X)
- Jorge Sánchez (ORCID: https://orcid.org/0000-0001-6341-783X)
- Pengpeng Wang (ORCID: https://orcid.org/0000-0003-2160-9360)
- Ana M. Giménez‐Arnau (ORCID: https://orcid.org/0000-0001-9548-5423)
- Michihiro Hide
- Isabelle Indermuehle
Institutions
- Nihon University (JP)
- Novartis (Switzerland) (CH)
- St. Michael's Hospital (CA)
- Universitat Pompeu Fabra (ES)
- University of Toronto (CA)
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Asthma and Allergy Foundation of America (US)
- Universidad de Antioquia (CO)
- Humboldt-Universität zu Berlin (DE)
- Hôpital Farhat Hached (TN)
- Novartis (India) (IN)
- Novartis (China) (CN)
- Hiroshima City Asa Citizens Hospital (JP)
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
- Houston Independent School District (US)
- Centro Universitário Fundação Santo André (BR)
- Smolensk State Medical University (RU)
- Hiroshima University Hospital (JP)
- National Taiwan University Hospital (TW)
- Hospital Universitário Clementino Fraga Filho (BR)
- Faculdade de Medicina do ABC (BR)
- Technical University of Munich (DE)
- University of Rzeszów (PL)
Publication Details
- Journal
- Allergy
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1111/all.70181
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- CSL Behring
- BioMarin Pharmaceutical
- Regeneron Pharmaceuticals
- Taiho Pharmaceutical
- Dermira
- Aimmune Therapeutics
- Celltrion
- Kaken Pharmaceutical
- Kyorin Pharmaceutical
- Eisai
- Galderma
- Mitsubishi Tanabe Pharma Corporation
- Sun Pharma
- LEO Pharma
- National Institutes of Health
- Genentech
- Novartis Pharma